In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Clinical Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.
The Bart Barlogie Clinical Investigator Award will be given to an investigator in recognition of their research in the myeloma field.
Shaji K. Kumar, MD, is Consultant in the Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota. He is the Chair of the Myeloma, Amyloidosis and Dysproteinemia Disease Group at Mayo Clinic, Research Chair for Division of Hematology, and Chair for Research in the Department of Medicine.
Dr. Kumar received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in Internal Medicine from the All India Institute of Medical Sciences, followed by an Internal Medicine residency and a hematology/oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. He then completed a Mayo Foundation Scholar at the Dana Farber Cancer Institute in Boston.
Dr. Kumar’s research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. He is the Principal Investigator of several phase 1, 2 and 3 clinical trials. He also focuses on the mechanisms of disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Dr. Kumar serves as Chair of the NCCN Multiple Myeloma Guidelines Panel. He is the President Elect of the International Society of Amyloidosis and the President Elect of the International Myeloma Society. He is the current Editor-in-Chief of The Hematologist.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.